LivFul | Safe medicines for the world’s underserved populations

LivFul Philosophy

When we innovate for those with the least access, we innovate better, creating health and wealth for all

Step

Discover safe medicines

We find the most innovative and overlooked IP and activate it for the global south. That IP comes from scientists who are inspired to accelerate the global impact of their assets. IP like non-opioid pain relief or wound-healing compound.

The Global South is madeup of countries in

Africa

Asia

Latin America

Africa

Asia

Latin America

Step

Develop early clinical validation

We partner with local health systems across developing countries to de-risk drug programs by using early stage, small-scale human efficacy trials at lower costs and to exacting US FDA standards.

Phase one

Step

Distribute equitably

We obtain regulatory approval to allow out-licensing to global north pharmaceutical partners and utilize public/private partnerships for distribution in the global south.

Access for all

Our Top assets

Medicine made for the global south reaps huge benefits the world over

Staytec™

A next-gen, life-saving insect repellent

The context in developing countries made conventional repellents ineffective. As a response we developed a patented, non-toxic, aromatic repellent that offers unparalleled protection from malaria and other mosquito-borne diseases.

A packet of Akiva Anti-Mosquito Lotion with a Staytec badge.

Mosquito landings

-98%

Protection time

14hrs

Malaria cases

-100%

LV201R Tablet

Novel, safe treatment for glioblastoma

Conventional cancer treatments can be impractical in the global south. That's why we’re innovating a safe cancer treatment, LV201R, for glioblastoma and LV101R for the treatment of gastrointestinal and colorectal cancers. Our treatments have potential to replace chemotherapy and serve as a broad-spectrum therapy for a variety of cancers.

Suppressed tumor growth and reduced volume in mouse model

Anti-tumor and anti-angiogenic activity in chicken membrane

Promoted apoptosis in numerous cancer cell lines

More L.I.F.E. solutions in development

We believe in L.I.F.E. - Liberating Innovation For Everyone. Together with our partners, we're tackling the largest disease burdens in the world to achieve our mission of improving the quality of L.I.F.E. for a billion people everyday.

Suppressed tumor growth and reduced volume in mouse model
Anti-tumor and anti-angiogenic activity in chicken membrane

Origin story

As a child in Nigeria, I battled constant malarial infection

Desperate for a solution, I formulated my own insect repellent at the age of 10 before I knew they even existed.

That’s why I’m fighting for health access for all

2%
83% of the global population lives in developing countries. But, they receive only 2% of the R&D spend on health.
1%
90% of the global disease burden is located in the global south. Only 1% of health research funding addresses diseases predominantly affecting the global south, like NTDs.
2.4T
The fastest growing health markets are emerging in global south. Healthcare spend is expected to reach 2.4 trillion dollars.

We can save tens of millions of lives by treating preventable diseases. And, we can expand the wealth of consumers and investors alike while we do so.

10M

The LivFul Team

Our impact is driven by innovative entrepreneurs and organizations across the world

Yaw Nsarkoh

Chairman of the board

Hogan Bassey

Founder & Co-CEO

Matt Elsberry

Co-Chief Executive Officer

Alexander Zomignani

CEO, Therapeutics

Andy Mahler

Co-Founder and CEO, Global Health

Dr. John Ridden

Chief Scientific Officer

Dr. Luiz Pianowski

Global Director, R&D

Kevin Engel

Chief Finance Officer

John Manwell

Chief Operations Officer

Investors

Today’s investors will be at the forefront of global health

98% of the world’s medical R&D is spent in the global north. But, medicines developed for the global south, like non-toxic cancer therapies, impact everyone. Help us drive the future of healthcare.

Request investor deck

Global health